Cargando…

Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity have been suggested...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Doo Yong, Kang, Dong Hyuk, Kim, Jong Won, Kim, Do Kyung, Lee, Joo Yong, Hong, Chang Hee, Cho, Kang Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017207/
https://www.ncbi.nlm.nih.gov/pubmed/31861415
http://dx.doi.org/10.3390/cancers12010008
_version_ 1783497149847175168
author Chung, Doo Yong
Kang, Dong Hyuk
Kim, Jong Won
Kim, Do Kyung
Lee, Joo Yong
Hong, Chang Hee
Cho, Kang Su
author_facet Chung, Doo Yong
Kang, Dong Hyuk
Kim, Jong Won
Kim, Do Kyung
Lee, Joo Yong
Hong, Chang Hee
Cho, Kang Su
author_sort Chung, Doo Yong
collection PubMed
description Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity have been suggested. Therefore, we conducted a meta-analysis to compare oncologic outcomes between the treatment sequences of ABI-ENZA and ENZA-ABI in patients with mCRPC. The primary endpoint was a combined progression-free survival (PFS), and the secondary endpoint was overall survival (OS). A total of five trials on 553 patients were included in this study. Each of the included studies was retrospective. In two studies including both chemo-naïve and post-chemotherapy mCRPC patients, for ABI-ENZA compared with ENZA-ABI, pooled hazard ratios (HRs) for PFS and OS were 0.37 (p < 0.0001; 95% confidence intervals (CIs), 0.23–0.60) and 0.64 (p = 0.10; 95% CIs, 0.37–1.10), respectively. In three studies with chemo-naïve mCRPC patients only, for ABI-ENZA compared with ENZA-ABI, pooled HRs for PFS and OS were 0.57 (p = 0.02; 95% CIs, 0.35–0.92) and 0.86 (p = 0.39; 95% CIs, 0.61–1.21), respectively. The current meta-analysis revealed that ABI-ENZA had a significantly more favorable oncological outcome, but the level of evidence was low. Therefore, large-scale randomized trials may be needed.
format Online
Article
Text
id pubmed-7017207
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70172072020-02-28 Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis Chung, Doo Yong Kang, Dong Hyuk Kim, Jong Won Kim, Do Kyung Lee, Joo Yong Hong, Chang Hee Cho, Kang Su Cancers (Basel) Article Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity have been suggested. Therefore, we conducted a meta-analysis to compare oncologic outcomes between the treatment sequences of ABI-ENZA and ENZA-ABI in patients with mCRPC. The primary endpoint was a combined progression-free survival (PFS), and the secondary endpoint was overall survival (OS). A total of five trials on 553 patients were included in this study. Each of the included studies was retrospective. In two studies including both chemo-naïve and post-chemotherapy mCRPC patients, for ABI-ENZA compared with ENZA-ABI, pooled hazard ratios (HRs) for PFS and OS were 0.37 (p < 0.0001; 95% confidence intervals (CIs), 0.23–0.60) and 0.64 (p = 0.10; 95% CIs, 0.37–1.10), respectively. In three studies with chemo-naïve mCRPC patients only, for ABI-ENZA compared with ENZA-ABI, pooled HRs for PFS and OS were 0.57 (p = 0.02; 95% CIs, 0.35–0.92) and 0.86 (p = 0.39; 95% CIs, 0.61–1.21), respectively. The current meta-analysis revealed that ABI-ENZA had a significantly more favorable oncological outcome, but the level of evidence was low. Therefore, large-scale randomized trials may be needed. MDPI 2019-12-18 /pmc/articles/PMC7017207/ /pubmed/31861415 http://dx.doi.org/10.3390/cancers12010008 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chung, Doo Yong
Kang, Dong Hyuk
Kim, Jong Won
Kim, Do Kyung
Lee, Joo Yong
Hong, Chang Hee
Cho, Kang Su
Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_full Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_fullStr Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_full_unstemmed Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_short Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_sort comparison of oncologic outcomes between two alternative sequences with abiraterone acetate and enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017207/
https://www.ncbi.nlm.nih.gov/pubmed/31861415
http://dx.doi.org/10.3390/cancers12010008
work_keys_str_mv AT chungdooyong comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT kangdonghyuk comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT kimjongwon comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT kimdokyung comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT leejooyong comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT hongchanghee comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT chokangsu comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis